Monitoring the effects of disease-modifying drugs on the health of people with multiple-sclerosis - Assessing the relevance of antibodies to interferon-beta and Copaxone
Phase of Trial: Phase III
Latest Information Update: 17 Jun 2016
At a glance
- Drugs Glatiramer acetate (Primary) ; Interferon beta (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 16 Jun 2013 Planned End Date changed from 1 Aug 2015 to 1 Jun 2013 as reported by United Kingdom Clinical Research Network record.
- 16 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
- 27 Jan 2013 Accrual to date is 64% according to United Kingdom Clinical Research Network record.